Theravance Biopharma Gears Up for Key Investor Event
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to host an engaging virtual key opinion leader (KOL) investor event dedicated to discussing its clinical development program for ampreloxetine. This event, taking place on December 8, 2025, promises to shed light on significant advancements in the treatment landscape for symptomatic neurogenic orthostatic hypotension (nOH).
Highlighting Unmet Needs in Neurogenic Orthostatic Hypotension
Leading the discussion will be Dr. Horacio Kaufmann from NYU Langone Health, who will elaborate on the critical medical needs patients face with symptomatic nOH caused by multiple system atrophy (MSA). With the condition drastically affecting approximately 80% of MSA patients, understanding treatment opportunities is paramount. Dr. Kaufmann's insights will share breakthroughs in addressing these challenges through ampreloxetine.
Anticipating Phase 3 CYPRESS Study Results
The spotlight of the event will focus on the ampreloxetine Phase 3 CYPRESS study's topline data, expected in early 2026. This study aims to evaluate the medication's efficacy and safety in treating nOH, and will draw on positive outcomes from the prior REDWOOD study. This session will explore strategic design choices and the commercial potential of ampreloxetine in addressing the nuances of MSA treatment.
Critical Aspects of the CYPRESS Study
CYPRESS (Study 0197) is a multi-center, randomized withdrawal study that assesses the efficacy of ampreloxetine after a treatment period of 20 weeks. The primary outcome is based on the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, which evaluates the drug's impact on daily functioning and quality of life for MSA patients suffering from nOH.
Understanding Multiple System Atrophy
Multiple system atrophy is a complex progressive neurological disorder that impairs both movement and autonomic functions. Patients often suffer from debilitating nOH symptoms, which manifest as a significant drop in blood pressure upon standing, leading to dizziness and fainting spells. Awareness of these symptoms is crucial for seeking appropriate treatment.
About Ampreloxetine's Development
Ampreloxetine, designed as a once-daily selective norepinephrine reuptake inhibitor, shows promise in improving norepinephrine levels and managing blood pressure effectively. The investigational drug holds the potential to transform care strategies for patients experiencing inadequate relief from current therapies.
About Theravance Biopharma
Theravance Biopharma dedicates itself to developing innovative solutions that truly make a difference in patients' lives. Beyond ampreloxetine, the company is known for its FDA-approved YUPELRI® (revefenacin), reinforcing its commitment to ensure effective treatment options for serious health conditions like chronic obstructive pulmonary disease (COPD). As the field of neurology advances, Theravance remains at the forefront, aiming to enhance treatment landscapes for more patients.
Frequently Asked Questions
What is the focus of the upcoming KOL event hosted by Theravance Biopharma?
The event will primarily focus on the clinical development program for ampreloxetine, discussing the ongoing Phase 3 CYPRESS study and future directions.
Who will be presenting at the event?
Dr. Horacio Kaufmann from NYU Langone Health will join Theravance Biopharma's management to discuss key findings related to nOH and MSA.
What is the significance of the Phase 3 CYPRESS study?
This study aims to evaluate the efficacy of ampreloxetine in treating symptomatic nOH, with topline results expected in early 2026.
How does nOH affect patients with MSA?
Patients with MSA and nOH can experience severe drops in blood pressure upon standing, leading to symptoms like dizziness and fainting, drastically impacting their daily lives.
What positions does Theravance Biopharma hold in the pharmaceutical industry?
Theravance Biopharma is recognized for its commitment to developing transformative therapies, with a focus on conditions such as COPD and MSA.
